Tenaya CEO granted 732K options, 122K RSUs

Tenaya Therapeutics granted its CEO a large option and RSU package with long-term vesting.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. (symbol: TNYA) is the issuer of record for a Form 4 filing submitted to the SEC. Ali Faraz reported acquisition or exercise transactions in this Form 4 filing.

Tenaya Therapeutics, Inc. (TNYA) reported that Chief Executive Officer and director Ali Faraz received equity awards on September 10, 2026. He was granted 732,500 stock options exercisable at $0.6488 per share and 122,000 restricted stock units, all under the Amended and Restated 2021 Equity Incentive Plan, with multi-year vesting schedules.

Insider Trade Summary

Grant/Award: 854,500 shares

Grant/Award 2 txns

Insider Ali Faraz

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy) F4	732,500	$0.00	$0.00
Grant/Award	Common Stock F1, F2, F3	122,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 732,500 contracts (Direct); Common Stock — 539,782 shares (Direct)

Footnotes (4)

1. F1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.
2. F2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.
3. F3. Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
4. F4. Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

Key Figures

Stock options granted: 732,500 options Option exercise price: $0.6488 per share RSUs granted: 122,000 restricted stock units +4 more

7 metrics

Stock options granted 732,500 options Grant to CEO Ali Faraz on September 10, 2026

Option exercise price $0.6488 per share Exercise price for 732,500 stock options granted September 10, 2026

RSUs granted 122,000 restricted stock units Equity award to CEO on September 10, 2026

Common shares after award 539,782 shares CEO’s reported common stock holdings following September 10, 2026 transaction

Unvested RSU component 384,069 shares Included within reported common stock, to be issued upon RSU vesting

Option expiration date September 9, 2036 Expiration for 732,500 stock options granted to CEO

Initial RSU vesting date February 15, 2027 Vesting of first 1/8 of 122,000 RSUs

Key Terms

restricted stock units, economic equivalent, Equity Incentive Plan, vesting

4 terms

restricted stock units financial

"Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

economic equivalent financial

"Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock."

Equity Incentive Plan financial

"pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"will vest as to 1/8th of the total number of shares subject to the restricted stock unit award"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did TNYA grant to CEO Ali Faraz on September 10, 2026?

Tenaya Therapeutics granted Ali Faraz 732,500 stock options at an exercise price of $0.6488 per share and 122,000 restricted stock units, all under the Amended and Restated 2021 Equity Incentive Plan, with vesting over several years.

What are the vesting terms for the 122,000 RSUs granted by TNYA to the CEO?

The 122,000 RSUs granted to Ali Faraz vest as to 1/8 of the total on February 15, 2027, and 1/8 every six months thereafter until fully vested, assuming continued service.

How do the 732,500 stock options for TNYA’s CEO vest?

The 732,500 stock options vest as to 1/48 of the total one month after the September 10, 2026 grant date, and 1/48 on each monthly anniversary thereafter until fully vested, subject to continued service.

What is the exercise price and term of the new TNYA stock options granted to the CEO?

The stock options granted to Ali Faraz have an exercise price of $0.6488 per share, become exercisable starting October 10, 2026 based on their vesting schedule, and have an expiration date of September 9, 2036.

How many TNYA common shares does the CEO hold after these transactions?

After the September 10, 2026 grants, Ali Faraz is reported as holding 539,782 shares of common stock, which includes 384,069 shares that will be issued upon vesting of restricted stock units.

Were the TNYA CEO’s September 10, 2026 equity grants made under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not affirmed, and no footnote states that the September 10, 2026 equity awards to Ali Faraz were made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 08:11 PM Accepted by SEC EDGAR 09/11/2026 - 08:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Faraz

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	09/10/2026(2)		A		122,000	A	$0	539,782(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.6488	09/10/2026		A		732,500		10/10/2026(4)	09/09/2036	Common Stock	732,500	$0	732,500	D

Explanation of Responses:

1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

3. Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

	/s/ Jennifer Drimmer Rokovich, Attorney in Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)